ASH 2021 | Treating MDS patients during the COVID-19 pandemic
David Sallman
• 11 Dec 2021
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, shares some insights and advice into the treatment of patients during the COVID-19 pandemic, highlighting the importance of vaccination and the protection offered to patients at this time. Dr Sallman mentions the need to focus on novel drug combinations and preventative measures in the future, especially for patients with high-risk myelodysplastic syndromes (HR-MDS), as the current standard of care with azacitidine and decitabine is not adequate for patients who do not respond to these agents. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
